Anúncio
Anúncio

NVCT

NVCT logo

Nuvectis Pharma, Inc. Common Stock

8.46
USD
Patrocinado
-0.38
-4.24%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pré-Mercado

8.47

+0.01
+0.18%

Relatórios de Lucros NVCT

Rácio de surpresa positiva

NVCT separação 5 de 15 últimas estimativas.

33%

Próximo Relatório

Data do Próximo Relatório
23 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.30
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
-9.09%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-16.67%

Nuvectis Pharma, Inc. Common Stock earnings per share and revenue

On 04 de nov. de 2025, NVCT reported earnings of -0.33 USD per share (EPS) for Q3 25, missing the estimate of -0.25 USD, resulting in a -30.69% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of -0.30 USD, with revenue projected to reach -- USD, implying an diminuir of -9.09% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Nuvectis Pharma, Inc. Common Stock reported EPS of -$0.33, missing estimates by -30.69%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.55%, changed from $6.36 before the earnings release to $5.88 the day after.
The next earning report is scheduled for 23 de fev. de 2026.
Based on 6 analistas, Nuvectis Pharma, Inc. Common Stock is expected to report EPS of -$0.30 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio